Differences were evident in the rate of mutations, with ZBTB16‐RARA+ cases characterized by about two mutations/patient, while there were a median of 0.9 and 2.9 mutations/patient in samples collected from APL and non‐RARA rearranged AMLs. This evidence concerns the gene ZBTB16 and acute promyelocytic leukemia.